Red blood cells (RBCs) are biocompatible carriers that can be employed to deliver different bioactive substances. In the past few decades, many strategies have been developed to encapsulate or attach drugs to RBCs. Osmotic-based encapsulation methods have been industrialized recently, and some encapsulated RBC formulations have reached the clinical stage for treating tumors and neurological diseases. Inspired by the intrinsic properties of intact RBCs, some advanced delivery strategies have also been proposed. These delivery systems combine RBCs with other novel systems to further exploit and expand the application of RBCs. This review summarizes the clinical progress of drugs encapsulated into intact RBCs, focusing on the loading and clinical trials. It also introduces the latest advanced research based on developing prospects and limitations of intact RBCs drug delivery system (DDS), hoping to provide a reference for related research fields and further application potential of intact RBCs based drug delivery system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biomaterials.2021.121202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A New Anti-Interfering Platelet Counting Technology Utilizing Conventional Impedance and White Blood Cell Differential Channel.
Int J Lab Hematol
January 2025
Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Introduction: Accurate platelet (PLT) counting is crucial for disease diagnosis and treatment, especially under the condition of thrombocytopenia and platelet transfusion. A few PLT counting approaches have been established including impedance and fluorescent methods. The impedance PLT counting (PLT-I) approach could be interfered by small non-PLT particles in the blood, such as RBC/WBC fragments, microcytes, bacteria, and cryoglobulins.
View Article and Find Full Text PDFStructural and functional significance of two conserved lysine residues in acylated sites of Kingella kingae RtxA cytotoxin.
Biochimie
December 2024
Institute of Microbiology of the Czech Academy of Sciences, v.v.i., 142 20, Prague, Czech Republic. Electronic address:
Kingella kingae, an emerging pediatric pathogen, secretes the pore-forming toxin RtxA, which has been implicated in the development of various invasive infections. RtxA is synthesized as a protoxin (proRtxA), which gains its biological activity by fatty acylation of two lysine residues (K558 and K689) by the acyltransferase RtxC. The low acylation level of RtxA at K558 (2-23 %) suggests that the complete acylation at K689 is crucial for toxin activity.
View Article and Find Full Text PDFLeucinostatins target Plasmodium mitochondria to block malaria transmission.
Parasit Vectors
December 2024
Department of Biological Sciences, Florida International University, 11200 SW 8th St, Miami, FL, 33199, USA.
Background: Malaria remains a critical disease. Leucinostatins from the fungus Purpureocillium lilacinum inhibited the transmission of Plasmodium falciparum to mosquitoes via contact.
Methods: Here, we modified the leucinostatin B (LB) C-terminus to make derivatives and examined their inhibition against malaria transmission to mosquitoes.
Hypoxia induces robust ATP release from erythrocytes in ApoE-LDLR double-deficient mice.
Front Physiol
November 2024
Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Krakow, Poland.
Red blood cells (RBCs) play a role in the regulation of vascular tone via release of adenosine triphosphate (ATP) into the vasculature in response to various stimuli. Interestingly, ApoE/LDLR double-deficient (ApoE/LDLR) mice, a murine model of atherosclerosis, display a higher exercise capacity compared to the age-matched controls. However, it is not known whether increased exercise capacity in ApoE/LDLR mice is linked to the altered ATP release from RBCs.
View Article and Find Full Text PDFThe Molecular Determinants of Erythrocyte Removal Impact the Development of Metabolic Dysfunction-Associated Steatohepatitis.
Endocr Metab Immune Disord Drug Targets
December 2024
Laboratory of Biochemistry, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Metabolic dysfunction-associated steatohepatitis (MASH) is a major cause of a worldwide clinical and financial burden. Despite the tremendous efforts for untangling the molecular mechanisms, there is still a need for defining specific therapeutic targets. In this editorial, the author will focus on the role of erythrocyte death and hepatic erythrophagocytosis in MASH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!